45 results on '"Catalano, Gianfranco"'
Search Results
2. PB1787: PLZF-RARΑ ENHANCES METABOLIC PLASTICITY AND ROS SCAVENGING IN AML CELLS
3. Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms
4. Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment
5. Hepatocyte Growth Factor and Macrophage Inflammatory Protein 1β: Structurally Distinct Cytokines that Induce Rapid Cytoskeletal Changes and Subset-Preferential Migration in T Cells
6. NPM1 mutated, BCR-ABL1 positive myeloid neoplasms: review of the literature
7. Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes
8. The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
9. The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
10. NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
11. PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells
12. Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies
13. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy
14. PML/RARAinhibits expression ofHSP90 and its targetAKT
15. Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors
16. PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells
17. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia: Presented in part at the 41st Annual Meeting of the American Society of Hematology, December 3-7, 1999, New Orleans, LA.
18. Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation
19. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro
20. Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia
21. PML/RARA inhibits expression of HSP90 and its target AKT.
22. Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms
23. PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity
24. A case of SRSF2 mutation in chronic lymphocytic leukemia
25. Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
26. Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes
27. Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy
28. Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis
29. Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia
30. Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia
31. Rituximab Consolidation and Maintenance Immunotherapy Improve Outcome in B-Cell Chronic Lymphocytic Leukemia.
32. Nucleophosmin Gene Mutations Exhibit High Spontaneous Apoptosis and Favorable Prognosis in Acute Myeloid Leukemia.
33. High CD69 Protein Expression Predicts a Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia (B-CLL).
34. PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells
35. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant.
36. Induction of Apoptosis by Pyrrolobenzothiadiazepines (PBTDs) in Cell Lines and in 12 Chronic Myeloid Leukemia Patients at Onset and Imatinib-Resistant.
37. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
38. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation
39. A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype
40. Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2Splicing Factor Gene Mutations in Myelodysplastic Syndromes
41. PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity
42. Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.
43. PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs)induce apoptosis in K562 cells.
44. PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells.
45. NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.